HanAll Biopharma FY 2025 Annual ReportBeta
HanAll Biopharma annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
HanAll Biopharma FY 2025 Annual Report Analysis
Business Overview
- • FY2025 consolidated revenue KRW 155.2B, +12% YoY; operating loss KRW 915M vs. operating profit KRW 230M prior year
- • Batoclimab (HL161BKN) Phase 3 MG topline data released Mar 2025, showing superior efficacy vs. competitors; TED Phase 3 topline expected H1 2026
Management Discussion & Analysis
- • Revenue KRW 155.2B (+12% YoY, 6th consecutive record high); operating loss KRW 916M (vs. OP KRW 230M prior year, deficit reversal); net loss KRW 5.6B (vs. net loss KRW 1.8B)
- • 'Biotop' probiotic drug achieved annual sales KRW 23.5B; hair-loss product line exceeded KRW 10B; batoclimab (HL161BKN) milestone revenue KRW 8.1B (+18% YoY) — MG and CIDP trial completion recognized
Risk Factors
- • USD 10% move → ±KRW 515.4M pre-tax impact, up from ±KRW 364.0M prior year; net USD liability position KRW 5.15B
- • Total borrowings KRW 30.7B newly added vs zero prior year, lifting debt ratio from 26.45% to 39.30%
HanAll Biopharma FY 2025 Key Financial MetricsDART
Total Assets
KRW 225.2B
▲ +5.8% YoY
Operating Cash Flow
-KRW 2.3B
▼ -125.0% YoY
CapEx
KRW 948.0M
▼ -42.3% YoY
Source: KIFRS consolidated financial data from HanAll Biopharma annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding